Equities Analysts Issue Forecasts for WVE FY2026 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE) – Equities research analysts at B. Riley lowered their FY2026 earnings estimates for Wave Life Sciences in a report issued on Thursday, April 10th. B. Riley analyst M. El-Saadi now expects that the company will post earnings per share of ($1.15) for the year, down from their previous estimate of ($0.96). The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. B. Riley also issued estimates for Wave Life Sciences’ FY2027 earnings at ($0.25) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.84 EPS.

Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.34. The firm had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%.

Other equities research analysts have also recently issued research reports about the stock. Jefferies Financial Group started coverage on shares of Wave Life Sciences in a research report on Tuesday, February 25th. They issued a “buy” rating and a $26.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Wave Life Sciences in a report on Wednesday, March 26th. Wedbush began coverage on Wave Life Sciences in a report on Tuesday, April 8th. They set an “outperform” rating and a $18.00 price objective on the stock. Finally, StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.18.

Wave Life Sciences Stock Up 4.7 %

Wave Life Sciences stock opened at $6.28 on Monday. The stock has a 50-day simple moving average of $9.21 and a 200 day simple moving average of $11.63. The stock has a market capitalization of $963.89 million, a price-to-earnings ratio of -5.66 and a beta of -0.93. Wave Life Sciences has a 12-month low of $4.25 and a 12-month high of $16.74.

Institutional Trading of Wave Life Sciences

Hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new stake in shares of Wave Life Sciences in the fourth quarter worth about $40,000. Quarry LP bought a new position in shares of Wave Life Sciences during the 4th quarter valued at about $62,000. KBC Group NV acquired a new position in shares of Wave Life Sciences in the 4th quarter valued at approximately $67,000. Summit Investment Advisors Inc. increased its stake in Wave Life Sciences by 31.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after purchasing an additional 2,308 shares in the last quarter. Finally, Westwood Wealth Management bought a new stake in Wave Life Sciences during the 4th quarter worth approximately $124,000. Institutional investors and hedge funds own 89.73% of the company’s stock.

Insider Activity

In other Wave Life Sciences news, CEO Paul Bolno sold 169,025 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $9.57, for a total value of $1,617,569.25. Following the sale, the chief executive officer now directly owns 338,351 shares in the company, valued at approximately $3,238,019.07. This trade represents a 33.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the transaction, the director now directly owns 16,115 shares in the company, valued at approximately $157,443.55. This represents a 39.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by company insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.